Expression of Sex Hormones in Oral Squamous Cell Carcinoma: A Systematic Review on Immunohistochemical Studies

Saranya R 1, Chandini R 1, Khadijah Mohideen 1, Pooja N. Adtani 2, Vijayanirmala Subramani 3, Murali Balasubramaniam 3

1. Oral and Maxillofacial Pathology, Sathyabama Dental College and Hospital, Sathyabama Institute of Science and Technology, Chennai, IND
2. Basic Medical and Dental Sciences, College of Dentistry, Gulf Medical University, Ajman, ARE
3. Oral and Maxillofacial Pathology, Faculty of Dental Sciences, Sri Ramachandra Institute of Higher Education and Research, Chennai, IND

Corresponding author: Saranya R, saranyaramsridhar@gmail.com

Abstract

Oral squamous cell carcinoma (OSCC) is the most widespread oral malignancy. In the western world, smoking and alcohol remain the most common risk factors, whereas smokeless tobacco and areca nut consumption are the prevalent etiological factors in South Asia. Numerous markers were studied till date to identify the disease. However, the role of sex hormones in OSCC is poorly defined. Hormonal receptors play a role in breast cancer, prostate cancer, and human papillomavirus (HPV) driven oropharyngeal cancers. It is proven that the expression of estrogen receptor-α improved the overall survival of the patient with HPV-positive oropharyngeal cancer. Thus, this review article aims to determine the expression of sex hormones by immunohistochemistry in OSCC.

This systematic review was performed with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement Criteria 2020. Relevant articles were collected from the electronic database in PubMed and Cochrane till 2021. Immunohistochemical studies on sex hormones and their role in OSCC published in English literature were included. We excluded case reports, case series, and abstract-only articles. The sample size of the selected studies varied, and these studies measured the parameters such as sex hormones and OSCC. Furthermore, all the studies used different sex hormones and their association with oral cancer through the immunohistochemical process. Thus, this review summarizes that sex hormones influence the biopathology of oral cancer and have a prognostic significance in the tumor subgroups.

Introduction And Background

Oral squamous cell carcinoma (OSCC) is the most commonly occurring cancer in the head and neck region, with an estimate of 6,50,000 new cases worldwide every year [1]. The mortality rate of oral cancer is high, with 4,50,000 deaths per year. Several etiological factors, such as smoking and alcohol consumption, play a role in causing the disease with the occurrence being high in males [2]. Numerous markers, such as cytokeratin 19 (CK19), cytokeratin 8 (CK8), beta 2-microglobulin, cluster of differentiation (CD) 44, CD80, p53, C-X-C chemokine receptor type 4 (CXCR4), CC chemokine receptor 7, p16, pRb, human papillomavirus deoxyribonucleic acid (HPV DNA), and E6/E7 viral genes, play an important role in predicting the metastasis and prognosis in head and neck squamous cell carcinoma (HNSCC) patients [3]. Sex hormones were more frequently detected to play a major role in breast cancer, prostate cancer, and oropharyngeal tumors, but their involvement in HNSCC remains controversial [4]. Multiple studies were undertaken to define the expression of hormonal receptors in oral cancer and its potential clinical significance. Cancers with different pathological characteristics and treatment responses depend on the expression of sex hormone receptors [5]. Currently, several hormonal therapies are available to treat specific tumors such as androgen-dependent prostate cancer (e.g., enzalutamide) and human epidermal growth factor receptor 2 (HER2) positive breast cancers (e.g., tamoxifen). Howell et al. used immunohistochemistry (IHC) to detect androgen receptors (ARs) in the normal oral muccosa [6].

Estrogen receptor-α (ER-α) and estrogen receptor – β (ER-β) are located in either nucleus or cell cytoplasm of the normal mucosal cells and have a non-genomic effect. AR accumulation in the cytoplasm is associated with an increased risk of metastasis [7]. Aromatase, known as estrogen synthase, is responsible to convert androgen to estrogen. The expression of aromatase is correlated with increased ER-α/ER-β expression, reduced progesterone receptor (PR) expression, and increased cell proliferation and transcription of HPV oncogenes [8]. Interestingly, the expression of ER-α improved the overall survival of the patient with HPV-positive oropharyngeal cancer [9].

How to cite this article
R S, R C, Mohideen K, et al. (May 27, 2022) Expression of Sex Hormones in Oral Squamous Cell Carcinoma: A Systematic Review on Immunohistochemical Studies. Cureus 14(5): e25384. DOI 10.7759/cureus.25384
This systematic review aimed to determine the expression of sex hormones in OSCC through immunohistochemical studies and to conclude its protagonist action in the prognosis of the disease.

**Review Methodology**

The literature search was carried out on IHC studies that evaluated the role of sex hormones as markers in OSCC from 1984 to 2021 using PubMed and Cochrane databases.

**Search strategy**

**Keywords and Search Terms**

The search for a qualitative method of research was conducted using the SPIDER framework (Sample, Phenomenon of Interest, Design, Evaluation, and Research type). The keywords were discovered, and a list of synonyms and MeSH terms was developed to search. A Boolean operator search was established, and MeSH terms were as follows (Sex hormones AND OSCC), (IHC AND Sex hormones), (ER AND OSCC), (IHC AND AR).

**Inclusion and Exclusion Criteria**

The articles that were published in English from the year 1984 to 2021 were included in PubMed and Cochrane databases. A total of 516 articles were identified. This review included original research, observational studies, and randomized control study in human samples, which were based on the expression of various sex hormones by the IHC method. Studies were excluded if (i) they were in other languages, or were case reports, abstracts only articles, duplicates, and letters to the editor, (ii) were irrelevant, and (iii) used molecular techniques such as polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), and western blot. The articles were thoroughly analyzed based on the eligibility criteria, and later data were extracted.

**Review Process**

All the reviewers were involved in the entire review process. This included the various stages of the review process such as screening, data extraction, and observations in the study. The articles obtained by the Boolean search were screened for abstracts, and titles that encountered the inclusion criteria were organized. Furthermore, Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 was used in the process (Figure 1).

---

**FIGURE 1: PRISMA protocol: systematic review of included articles**

PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Results

After the initial electronic search, 516 articles were identified for the review process, of which 105 were marked as ineligible by using filters. Following this, 116 articles were removed using an automation tool for duplicate removal. Finally, after reviewing the abstracts and the full texts, seven articles were selected and included in the process.

Quality Assessment and Risk of Bias

The quality of the selected studies was assessed using The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies, which is performed based on the following three domains:

1. Selection
2. Comparability
3. Outcome

The study is awarded a maximum of one star for each domain. In addition, if the studies get a total score of less than 6, then the domain is deemed as "potential risk bias." On the other hand, if the score is more than 6, the study is deemed to have a "low risk bias." The full text of seven articles that met the criteria was assessed. Out of seven articles, two articles had a high risk of bias and the rest had a low risk (Table 1).

| Description | Selection | Comparability | Outcome |
|-------------|-----------|---------------|---------|
|             | Representativeness of the exposed cohort | Exposure | Outcome interest not present at the start | Comparability of cohorts based on the design | Comparability of cohorts based on the analysis | Assessment of outcome | Was follow-up long enough for outcomes to occur | Adequacy of follow-up of cohorts | Score* |
| Doll et al. | * | - | * | - | * | - | - | - | 5 |
| Chang et al. | * | * | * | * | * | * | * | - | 6 |
| Cotella et al. | * | * | * | * | * | * | * | - | 6 |
| Koenigs et al. | * | * | * | * | * | * | - | - | 5 |
| Lukito et al. | * | * | * | * | * | * | * | * | 7 |
| Marocchio et al. | * | * | * | * | * | * | * | * | 7 |
| Mohamed et al. | * | * | * | * | * | * | * | * | 8 |

TABLE 1: Assessment of quality and the risk of bias (NOS scale)

*Presence of criteria. *A score of less than 6 indicted potential risk bias and a score of more than 6 indicated a low risk bias.

NOS, Newcastle-Ottawa Scale

Data Extraction

Finally, the eligible articles were categorized, and the data were extracted. The following items were extracted from each included study: name of the title, authors, journal details, participants, age, sample size, markers used, study method, and area of expression. All the authors screened the available records. As a result, the following data were collected: participants, age, no. of patients, groups, markers used, study method, immunoreactive cases, and area of expression. The study results were tabulated and are given in Table 2.
### Prognostic Significance of ER-α in OSCC

Doll et al. [10]

| Title | Authors | Journal Details | Participants | Age | No. of Patients | Groups | Metastases | Study Method | Immunoreactive Cases | Area of Expression | Study Result |
|-------|---------|-----------------|--------------|-----|----------------|--------|------------|-------------|---------------------|------------------|--------------|
| Prognostic Significance of ER-α in OSCC | Doll et al. [10] | Cancers (Basel), Volume 13, Issue 22, pp. 576-3 | Primary tumor and primary lymph node metastases | 27-65 yrs | 216 | Male: 111; female: 105 | IHC | primary tumor: 11/132; primary lymph node metastatic: 5/62 | Nuclear staining | Increased ER-α expression in male patients and evaluated the aggressiveness |

### Regulation of ER-α function in OSCC cells by FAK signaling

Chang et al. [11]

| Title | Authors | Journal Details | Participants | Age | No. of Patients | Groups | Metastases | Study Method | Immunoreactive Cases | Area of Expression | Study Result |
|-------|---------|-----------------|--------------|-----|----------------|--------|------------|-------------|---------------------|------------------|--------------|
| Regulation of ER-α function in OSCC cells by FAK signaling | Chang et al. [11] | Endocrine-Related Cancer, Volume 21, Issue 4, pp. 355-65 | Benign and malignant tumors | - | 31 | - | ER-α | IHC and cell culture | Benign: 11; malignant tumors: 13/21 | Nuclear staining | FAK regulates ER-α function in OSCC cells |

### Expression of hormone receptors in OSCC

Cistlea et al. [12]

| Title | Authors | Journal Details | Participants | Age | No. of Patients | Groups | Metastases | Study Method | Immunoreactive Cases | Area of Expression | Study Result |
|-------|---------|-----------------|--------------|-----|----------------|--------|------------|-------------|---------------------|------------------|--------------|
| Expression of hormone receptors in OSCC | Cistlea et al. [12] | International Journal of Immunopathology and Pharmacology, Volume 24, Issue 2, pp. 129-52 | OSCC | 38-74 yrs | 20 | Male: 14; female: 6 | ER-α and AR | Reverse transcription PCR | 15/30 | Nuclear staining | The length of the AR modifies the transactivation activity in different cell types |

### Association of ER-α expression with survival in oropharyngeal cancer following chemoradiation therapy

Kanigke et al. [13]

| Title | Authors | Journal Details | Participants | Age | No. of Patients | Groups | Metastases | Study Method | Immunoreactive Cases | Area of Expression | Study Result |
|-------|---------|-----------------|--------------|-----|----------------|--------|------------|-------------|---------------------|------------------|--------------|
| Association of ER-α expression with survival in oropharyngeal cancer following chemoradiation therapy | Kanigke et al. [13] | Journal of the National Cancer Institute, Volume 111, Issue 9, pp. 503-42 | HPV-positive oropharyngeal cancer and primary chemoradiation therapy | 33-66 yrs | 515 | Male: 174; female: 41 | ER-α | IHC | HPV-positive oropharyngeal squamous cell carcinoma has an excellent prognosis with overall survival rates greater than 80% |

### Molecular identification, expression, and prognostic role of estrogen and PR in head and neck cancer

Lukie et al. [14]

| Title | Authors | Journal Details | Participants | Age | No. of Patients | Groups | Metastases | Study Method | Immunoreactive Cases | Area of Expression | Study Result |
|-------|---------|-----------------|--------------|-----|----------------|--------|------------|-------------|---------------------|------------------|--------------|
| Molecular identification, expression, and prognostic role of estrogen and PR in head and neck cancer | Lukie et al. [14] | International Journal of Oncology, Volume 30, Issue 1, pp. 155-60 | OSCC | 42-86 yrs | 69 | Male: 56; female: 13 | ER-α, β and PR | IHC and PCR | 27/69 | Nuclear staining | Coexpression of estrogen and PR: better prognosis |

### Estrogens and AR in OSCC

Marchetti et al. [15]

| Title | Authors | Journal Details | Participants | Age | No. of Patients | Groups | Metastases | Study Method | Immunoreactive Cases | Area of Expression | Study Result |
|-------|---------|-----------------|--------------|-----|----------------|--------|------------|-------------|---------------------|------------------|--------------|
| Estrogens and AR in OSCC | Marchetti et al. [15] | Acta otorhinolaryngologica, Volume 71, Issue 6, pp. 1513-9 | OSCC | 45-65 yrs | 60 | Male: 30; female: 30 | AR | Aromatase: ER-α and ER-β | AR: 16/60; aromatase: 8/60; ER-α: 5/60; ER-β: 23/60 | Nuclear staining | Aromatase expression: poorly differentiated |

### Expression of hormone receptors in oropharyngeal squamous cell carcinomas

Mohamed et al. [16]

| Title | Authors | Journal Details | Participants | Age | No. of Patients | Groups | Metastases | Study Method | Immunoreactive Cases | Area of Expression | Study Result |
|-------|---------|-----------------|--------------|-----|----------------|--------|------------|-------------|---------------------|------------------|--------------|
| Expression of hormone receptors in oropharyngeal squamous cell carcinomas | Mohamed et al. [16] | European Archives of Oto-Rhino-Laryngology, Volume 275, Issue 5, pp. 1288-300 | Oropharyngeal cancer and HPV-positive cases | - | 199 | Male: 147; female: 52 | AR ER2-PRE | IHC | AR: 31/199; ER: 126/199; PR: 54/199 | Nuclear staining | AR expression: invasive front of the tumor in HPV-related tumors, whereas PR expression is more in HPV-negative tumors |

### TABLE 2: Summary of study articles

| AR, androgen receptor; ER-α, estrogen receptor alpha; ER-β, estrogen receptor beta; HPV, human papillomavirus; IHC, immunohistochemistry; FAK, focal adhesion kinase; OSCC, oral squamous cell carcinoma; PR, progesterone receptor; PCR: polymerase chain reaction |

### Characteristics of the Study

These studies were reported under the guidelines of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement. All the studies included from 1984 to 2021 were considered, among which seven articles met the criteria, of which all were longitudinal studies with OSCC as a study sample. All the included cohort studies had participants with the primary tumor, primary lymph node metastasis, benign and malignant tumors, HPV-positive oropharyngeal cancer, and primary chemoradiation therapy. The included studies had both male and female cohorts, wherein different-sex hormones were used in the sample. The sex hormone markers showed immunopositivity in the nuclear area.

### Results of Individual Studies Based on the Outcome

Doll et al. concluded that patients with positive ER-α expression had significantly lower overall and relapse-free survival (RFS) than those with negative ER-α expression. For the primary tumor and primary
tumor/primary lymph node metastasis cohorts with ER-positive primary tumors, ER expression was significantly associated with overall survival (OS) and relapse-free survival in males but not in females [10]. There was a significant correlation between positivity and tumor localization. ER positivity in the primary tumor was correlated to the International Union against Cancer (UICC) TNM staging. The majority of cases were in stage IV and had a higher rate of bone infiltration [17].

Marocchio et al. demonstrated that ER-β was expressed in almost 40% of the cases and AR in 26%. However, AR expression presented statistically significant differences (p=0.025) between genders, four (13.3%) cases in women and 12 (40%) cases in men [15].

Lukits et al. reported a relatively high incidence of functional receptor expression (co-expression of ER and PR) in head and neck cancer regardless of the location of the tumor anatomy. The expressive number of cases expressing ER and PR indicate that hormones do not influence a patient’s survival but influence the progression of the lesion [14].

Koenigs et al. concluded that ER positivity in HPV-positive oropharyngeal cancers was associated with improved mortality on a general, disease-specific, progression-free, and relapse-free basis; statistically significant associations were maintained when clinical risks were adjusted, including the HPV status of the individual [13].

Discussion

Oral cancer is a leading problem worldwide, increasing OSCC incidence by around 2-6% every year [13]. It is a multifactorial and multistep process. The endocrine milieu is a vital factor in tumor progression, especially in tissues expressing the receptors such as the breast and prostate. Oral cancer is twice as common in men as in women. This difference may be related to the use of alcohol and tobacco, which is a major risk factor seen more commonly in men than in women. Although there is a significant influence of western culture upon the lifestyle, the incidence rate is less in females as women are spared due to the defense mechanism associated with the hormones and specific metabolic activity [14].

Egloff et al. reported a crosstalk between ERs and epidermal growth factors, which promotes tumor progression and poor prognosis [18]. Chan and Reade while analyzing the role of sex hormones in oral cancer observed that the hormones in an oral cancer patient are metabolized differently as compared to a healthy individual [19]. Other hormones such as luteinizing hormone, follicle-stimulating hormone, and prolactin also play a role in oral cancer and prove an alteration in the pituitary-adrenal-testicular axis. Similarly, Bauernhofer et al. reported that the prolactin receptor is an independent factor and affects the overall survival of patients diagnosed with head and neck cancer [20].

This systematic review aimed to analyze the role of sex hormones and their expression through IHC in OSCC. Therefore, this review summarized the key elements based on the published literature. Many research teams focused on the role of hormone receptors in hormone-dependent tissues. Lukits et al. were the first to report the role of ERs (both isoforms α and β) and progesterone receptors in head and neck cancer, laryngeal cancer, and oral cancers. More than 50% of cases showed positivity for messenger ribonucleic acid (mRNA) and protein expression of receptors [14].

Three primary mechanisms involved in tumorigenesis are receptor-mediated hormonal activity leading to cellular proliferation, increased mutation rates through cytochrome P450-mediated metabolic activation causing genotoxic effects, and induction of aneuploidy. Similarly, androgen and its receptors influence the transcription and translation process in normal cell development and differentiation [21]. Experimental studies show that androgen modulates the proto-oncogene expression (C-Myc) and apoptotic pathway (Bcl-2) [22,23]. Suba et al. [24] hypothesized that a deficiency of estrogen in postmenopausal women causes OSCC.

The clinical significance of sex hormones is addressed in many studies. Interestingly, the upregulation of ARs reduced the overall survival of patients with oral cancer, which was driven through micro RNA-21 [25]. However, there was a reduced disease-specific survival (p=0.001) associated with progesterone expression [16]. ER-α is associated with improved overall survival of HPV-positive oropharyngeal cancer and is probably influenced by the apolipoprotein B mRNA editing enzyme catalytic polypeptide (APOBEC) mutational signature, making these tumors more immunogenic [26]. In vivo, anti-estrogen therapies in transgenic mice against cervical cancer showed positive results. The expression of both ER-β and submaxillary gland androgen-regulated protein 3 (SMR3A) had a poor prognosis. This observation shows that ER-α activates multiple pathways in oral cancer to play a protective role or promote resistance [27].

Conclusions

This review highlights that sex hormones influence the biopathology of oral cancer and have a prognostic significance in tumor subgroups. Hormonal receptors were detected to play a major role in breast cancer, prostate cancer, and oropharyngeal tumors, but their involvement in HNSCC remained controversial. The expression of ER, AR, and PR need to be evaluated with prudence because of the probability of variation in
cleftopathological features and their association with different expression patterns in OSCC. Estrogen is known to be carcinogenic, and multiple mechanisms are involved in tumor promotion. Furthermore, estrogen has been shown to cause chromosomal instability, which leads to aneuploidy and the development of oral cancer. Lastly, ER expression could be regarded as a seldom risk factor for OSCC, and PR expression seems to be not relevant for the development of OSCC. Gene profiling techniques combined with molecular techniques could allow the interpretation of comprehensive studies in the future to diagnose and prevent the progression of OSCC.

### References

1. Lydiatt WM, Patel SG, O’Sullivan B, et al.: Head and Neck cancers—major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017, 67:122-37. 10.3322/caac.21589
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68:99-330. 10.3322/caac.21492
3. Dahiya K, Dhanakhar B: Updated overview of current biomarkers in head and neck carcinoma. World J Methodol. 2016, 6:77-86. 10.5662/wjm.v6i11.77
4. Contaldo M, Boccellino M, Zannini G, et al.: Sex hormones and inflammation role in oral cancer progression: a molecular and biological point of view. J Oncol. 2020, 2020:9587971. 10.1155/2020/9587971
5. Labrecque MP, Coleman IM, Brown LG, et al.: Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest. 2019, 129:4492-505. 10.1172/JCI128212
6. Howell A, Cuzick J, Baum M, et al.: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005, 365:60-2. 10.1016/S0140-6736(04)16766-6
7. Hewitt SC, Korach KS: Estrogen receptors: new directions in the new millennium. Endocr Rev. 2018, 39:664-75. 10.1210/er.2018-00087
8. Revankar CM, Cinino DF, Sklar LA, Artburn JR, Prossnitz ER: A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005, 307:1625-30. 10.1126/science.1106943
9. Zhou X, Wang S, Wang Z, et al.: Estrogen regulates Hippo signaling via GPER in breast cancer. J Clin Invest. 2015, 125:2123-35. 10.1172/JCI79757
10. Doll C, Bestendonk C, Kreutzler K, et al.: Prognostic Significance of Estrogen Receptor Alpha in Oral Squamous Cell Carcinoma. Cancers (Basel). 2021, 13:5763. 10.3390/cancers13225763
11. Chang YL, Hsu YK, Wu TP, et al.: Regulation of estrogen receptor α function in oral squamous cell carcinoma cells by FAK signaling. Endocr Relat Cancer. 2014, 21:555-66. 10.1530/ERC-14-0102
12. Colletta G, Izzo G, Carinci F, et al.: Expression of sexual hormones receptors in oral squamous cell carcinoma. Int J Immunopathol Pharmacol. 2011, 24:129-32. 10.1172/JIIMP.2011.2405222
13. Koenigs MB, Lefranc-Torres A, Bonilla-Velez J, et al.: Association of estrogen receptor alpha expression with survival in oropharyngeal cancer following chemoradiation therapy. J Natl Cancer Inst. 2011, 113:533-42. 10.1093/jnci/djr224
14. Lukits J, Remenář E, Rádó E, Ládányi A, Kážler M, Timár J: Molecular identification, expression and prognostic role of estrogen- and progesterone receptors in head and neck cancer. Int J Oncol. 2007, 30:155-60. 10.3892/ijo.30.1.155
15. Maroččio LS, Giudicic F, Corrêa L, Pinto Junior DdS, de Sousa SO: Oestrogens and androgen receptors in oral squamous cell carcinoma. Acta Odontol Scand. 2013, 71:1515-9. 10.3109/00016357.2013.775335
16. Mohamed H, Aro K, Jousi L, et al.: Expression of hormone receptors in oropharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2018, 275:1289-300. 10.1007/s00405-018-4949-9
17. Almangush A, Mäkitie AA, Triantafyllou A, et al.: Staging and grading of oral squamous cell carcinoma: an update. Oral Oncol. 2020, 107:104799. 10.1016/j.oraloncology.2020.104799
18. Egloff AM, Rothstein ME, Seethala R, Siegfried JM, Grandis JR, Stabile LP: Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res. 2009, 15:6529-40. 10.1158/1078-0432.CCR-09-0862
19. Chan SW, Reade PC: The role of ascorbic acid in oral cancer and carcinogenesis. Oral Dis. 1998, 4:120-9. 10.1111/j.1601-0825.1998.tb0028.x
20. Bauernhofer T, Pichler M, Wieckowski E, et al.: Prolactin receptor is a negative prognostic factor in patients with squamous cell carcinoma of the head and neck. Br J Cancer. 2011, 104:1641-8. 10.1038/bjc.2011.131
21. Russo J, Russo IH: The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol. 2006, 102:89-96. 10.1016/j.jsbmb.2006.09.004
22. Russo J, Hasan Lareef M, Balogh G, et al.: Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J Steroid Biochem Mol Biol. 2005, 87:1-25. 10.1016/j.jsbmb.2004.03.050
23. McEwan JJ: Molecular mechanisms of androgen receptor-mediated gene regulation: structure-function
analysis of the AF-1 domain. Endocr Relat Cancer. 2004, 11:281-95. 10.1677/erc.0.0110281
24. Suba Z: Gender-related hormonal risk factors for oral cancer. Pathology oncology research. 2007, 15:195-202. 10.1007/BF02895499
25. Lubov J, Maschietto M, Ibrahim I, et al.: Meta-analysis of microRNAs expression in head and neck cancer: uncovering association with outcome and mechanisms. Oncotarget. 2017, 8:55511-24. 10.18632/oncotarget.19224
26. Kano M, Kondo S, Wakita Y, et al.: Expression of estrogen receptor alpha is associated with pathogenesis and prognosis of human papillomavirus-positive oropharyngeal cancer. Int J Cancer. 2019, 145:1547-57. 10.1002/ijc.32500
27. Grünew J, Rong C, Hirschmann I, et al.: Regulation of submaxillary gland androgen-regulated protein 3A via estrogen receptor 2 in radioresistant head and neck squamous cell carcinoma cells. J Exp Clin Cancer Res. 2017, 36:25. 10.1186/s13046-017-0496-2